201 related articles for article (PubMed ID: 22755439)
1. Antibody-mediated rejection in heart transplant patients: long-term follow up of patients with high levels of donor-directed anti-DQ antibodies.
Ticehurst EH; Molina MR; Frank R; Kearns J; Lal P; Goldberg LR; Tsai D; Wald J; Kamoun M
Clin Transpl; 2011; ():409-14. PubMed ID: 22755439
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
4. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
[TBL] [Abstract][Full Text] [Related]
5. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
[TBL] [Abstract][Full Text] [Related]
6. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients.
Pavlova YA; Malek I; Honsova E; Netuka I; Sochman J; Lodererova A; Kolesar L; Striz I; Skibova J; Slavcev A
Tissue Antigens; 2010 Nov; 76(5):380-6. PubMed ID: 20604893
[TBL] [Abstract][Full Text] [Related]
8. Long-term post transplant alloantibody monitoring: a single center experience.
Ntokou IS; Boletis JN; Apostolaki M; Vrani V; Zavos G; Kostakis A; Iniotaki A
Clin Transpl; 2011; ():341-50. PubMed ID: 22755429
[TBL] [Abstract][Full Text] [Related]
9. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
[TBL] [Abstract][Full Text] [Related]
10. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection.
Hirai T; Kohei N; Omoto K; Ishida H; Tanabe K
Transpl Int; 2012 Sep; 25(9):925-34. PubMed ID: 22764746
[TBL] [Abstract][Full Text] [Related]
11. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
12. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
[TBL] [Abstract][Full Text] [Related]
13. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
14. Correlations of lymphocyte subset infiltrates with donor-specific antibodies and acute antibody-mediated rejection in endomyocardial biopsies.
Frank R; Dean SA; Molina MR; Kamoun M; Lal P
Cardiovasc Pathol; 2015; 24(3):168-72. PubMed ID: 25440957
[TBL] [Abstract][Full Text] [Related]
15. Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients.
Everly MJ
Clin Transpl; 2011; ():319-25. PubMed ID: 22755425
[TBL] [Abstract][Full Text] [Related]
16. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation.
Kayler LK; Farber JL; Colombe B; LaCava D; Friedewald JJ; Ratner LE
Transpl Int; 2006 Feb; 19(2):128-39. PubMed ID: 16441362
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
[TBL] [Abstract][Full Text] [Related]
18. A refractory case of subclinical antibody-mediated rejection due to anti-HLA-DQ antibody in a kidney transplant patient.
Fujimoto T; Nakada Y; Yamamoto I; Kobayashi A; Tanno Y; Yamada H; Miki J; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():81-5. PubMed ID: 26031594
[TBL] [Abstract][Full Text] [Related]
19. A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients.
Kimball PM; King A
Clin Transpl; 2011; ():369-72. PubMed ID: 22755433
[TBL] [Abstract][Full Text] [Related]
20. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]